On April 26, 2026, Sun Pharmaceutical Industries confirmed that it would acquire Organon & Co. (NYSE:OGN), a U.S. drugmaker, ...
Pharmaceutical company Organon (NYSE:OGN) missed Wall Street’s revenue expectations in Q1 CY2026, with sales falling 3.5% ...
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates ...
Stock index futures edged lower Monday morning as investors balanced cautious optimism ahead of this week's Big Tech earnings ...
Stocktwits on MSN
Why did NOK, OGN, XE stocks hit 52-week highs today?
Nokia rose more than 5%, climbing to an intraday high of $11.31, after Morgan Stanley, JPMorgan, and Argus increased price targets on the stock. ・Organon rose by over 1% to $13.38 after India-based ...
Organon (OGN) stock jumps as Sun Pharmaceutical Industries is moving ahead with a a $13B binding offer for the company. Read ...
The deal values Organon at about $11.75 billion and is expected to close in early 2027. ・The acquisition boosts Sun Pharma’s footprint across women’s health, biosimilars, and established branded ...
Organon & Co. (NYSE:OGN) was among the stocks on Jim Cramer’s Mad Money radar as he discussed the recent sell-off in ...
Sun Pharmaceutical Industries will buy U.S. drugmaker Organon & Co in an all-cash deal valued at about $11.75 billion ...
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.The proposed transaction may contain terms that could limit superior competing offers.Shareholders ...
Organon (OGN) stock soared 25% after Sun Pharma reportedly offered $13B for the women's healthcare firm, with Grünenthal and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results